Bioavailability
Conditions
Brief summary
A randomized, open-label, cross-over, single administration study to compare bioavailability of curcumin in health adults
Detailed description
* Randomization, Open-label, 3-period, 6-sequence, Crossover, Single * Drug-free inverval : more than 7 days * Sampling time : 0,0.5,1,1.5,2,3,4,6,8,12h
Interventions
DIETARY_SUPPLEMENTcurmin
curcumin 90mg/day cross-over
Sponsors
Handok Inc.
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
19 Years to 60 Years
Healthy volunteers
Yes
Inclusion criteria
1. Healthy adult 19 to 60 years 2. BMI 18.0\ 30.0kg/m2 at screening 3. Subject who was given, and fully understood, the information about the study, and has provided voluntary written informed consent to participate in the study and agreed to comply with the study requirements.
Exclusion criteria
1. A person with clinically significant disease corresponding to cardiovascular, respiratory, liver, kidney, digestive system, blood/tumor system, endocrine system, immune system, neuropsychiatry or who has a history within the last 6 months. 2. A person with a history of gastrointestinal disease or surgery (except for simple cecal surgery or hernia surgery) that may affect the absorption of food for clinical research. 3. Persons who have an irritable reaction to foods containing turmeric or other drugs and food. 4. Those who took medicines within 7 days before the first intake of food for clinical research. 5. Food for Clinical Research If you have consumed foods containing turmeric (eg, radishes, curry) within 7 days before the first intake of food, or you can't consume until the day of intake of food for the last clinical study. 6. Those who have participated in other clinical studies within 90 days prior to the first intake of food for clinical research. 7. Women who are pregnant or lactating during screening, or who plan to become pregnant during clinical research. A person who is deemed unsuitable for participating in this clinical study because of other reasons.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Cmax | 12hours | Maximum concentration at steady state |
| AUC | 12hours | Area under the concentration-time curve at steady state |
Countries
South Korea
Outcome results
None listed